Recently, the PROSE study, which used VeriStrat test to predict the efficacy of EGFR-TKIs, demonstrated EGFR-unknown or EGFR-WT NSCLC patients with VeriStrat “good” classification would have similar efficacy in second-line therapy using either chemo or EGFR-TKIs[29]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.